Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cyclo-Z in Obese Type 2 Diabetes
NCT02784275Phase 2Completed
- Sponsor
- NovMetaPharma Co., Ltd.
- Start
- Jun 2016
- Primary completion
- May 2017
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of cyclo(histidyl-proline) + zinc in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by NovMetaPharma Co., Ltd. Primary endpoints: Change of HbA1c Level From Baseline at 12 weeks and Change of Body Weight From Baseline at 12 weeks. Started Jun 2016; status: completed.
02
Drugs
cyclo(histidyl-proline) + zinc
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT02784275.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02784275.